Related Experiment Video
Updated: Feb 16, 2026

Electroretinogram Recording for Infants and Children under Anesthesia to Achieve Optimal Dark Adaptation and International Standards
Published on: September 3, 2020
Adaptive trials in paediatric development: dealing with heterogeneity and uncertainty in pharmacokinetic differences
Massimo Cella1, Meindert Danhof, Oscar Della Pasqua
1LACDR, Division of Pharmacology, Leiden University, Leiden, The Netherlands.
Insights
Adaptive dosing in pediatric trials optimizes drug exposure, improving efficacy compared to fixed doses. This approach enhances clinical trial power and understanding of dose-response relationships.
Area of Science:
- Pharmacokinetics and Pharmacodynamics
- Clinical Trial Design
- Pediatric Pharmacology
Background:
- Standard fixed-dose regimens in pediatric clinical trials may not achieve optimal drug exposure.
- Individual variability in pharmacokinetics can lead to sub-therapeutic or toxic drug levels.
- Optimizing dosing is crucial for demonstrating efficacy and safety in pediatric populations.
Purpose of the Study:
- To evaluate an adaptive trial design using variable dosing and controlled exposure.
- To compare the effectiveness of adaptive dosing versus fixed dosing in pediatric trials.
- To determine if adaptive designs improve dosing recommendations.
Main Methods:
- Simulated a pediatric clinical trial using a pharmacokinetic model for abacavir.
- Calculated area under the curve (AUC) for exposure and adapted doses to target levels.
- Compared exposure distributions between fixed-dose and controlled-exposure simulations.
Main Results:
- Fixed dosing resulted in 61 of 128 subjects outside the target exposure range (median AUC 6.43 mg·h/L).
- Adaptive dosing significantly narrowed the exposure distribution (median AUC 6.94 mg·h/L).
- Only 14 subjects deviated from the target exposure range after dose adjustment.
Conclusions:
- Adaptive randomization optimizes dosing regimens in early pediatric clinical trials.
- Randomizing to target exposure increases study power and probability of demonstrating efficacy.
- Adaptive designs enhance understanding of dose's role in clinical response heterogeneity.
Aims:
To assess whether an adaptive design in early clinical trials based on the paradigm of variable dosing and controlled exposure can provide better dosing recommendations compared with the standard fixed dose approach.
Methods:
In a clinical trial simulation setting, a paediatric study was simulated using a pharmacokinetic model previously developed for abacavir. Plasma concentrations following the current recommended dose (8 mg kg⁻¹) were taken at standard sampling times, exposures (AUC) were calculated and doses individually adapted to reach the target exposure (i.e. effective exposure in adults). A second round of simulations followed with the adapted doses, and the resulting concentrations were fitted again with the same model. Exposure distributions in both conditions (i.e. fixed dose and controlled exposure) were compared with the target exposure.
Results:
The AUC distribution after the current dose resulted in a median exposure of 6.43 mg h l⁻¹ (90th percentile 3.13-10.67 mg h l⁻¹). A total of 61 of 128 subjects showed AUC values either too low or to high compared with the target exposure. After dose adjustment, the median exposure was 6.94 mg h l⁻¹ (5.57-8.25 mg h l⁻¹), and only 14 subjects deviated from the target range.
Conclusions:
Adaptive randomization can be used to optimize dosing regimens in early paediatric clinical trials. The randomization of patients to target exposure rather than dose increases the probability of demonstrating efficacy (i.e. study power) compared with dose-controlled trials. Furthermore, it contributes to further understanding of the role of dose on the total heterogeneity in clinical response.
More Related Videos
Related Concept Videos
The Uncertainty Principle
Uncertainty in Measurement: Reading Instruments
Uncertainty: Overview
Uncertainty in Measurement: Accuracy and Precision
Uncertainty in Measurement: Significant Figures
Uncertainty: Confidence Intervals

